Key Highlights

  • Net loss narrowed to USD 2.5 million from USD 3.2 million a year earlier.
  • The loss was USD 0.24 per share, versus an estimated USD 0.27 loss.
  • Research and development expense fell to USD 890 thousand from USD 2.2 million.
  • General and administrative expense rose to USD 1.8 million from USD 1.1 million.

A Smaller Quarterly Loss on Lower Research Spending

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) reported a third-quarter net loss of USD 2,499 thousand versus USD 3,218 thousand, or USD 0.24 per share versus USD 5.76, compared with an estimated loss of USD 0.27 per share. The per-share comparison reflects a much larger weighted average share count of 10.6 million versus 558,868 a year earlier.

Research and development expense fell to USD 890 thousand from USD 2,197 thousand, while general and administrative expense rose to USD 1,775 thousand from USD 1,056 thousand. Total operating expenses were USD 2,665 thousand versus USD 3,253 thousand, and interest income rose to USD 169 thousand from USD 37 thousand.

The filing attributes the USD 1.3 million decline in Research and Development mainly to a decrease of approximately USD 1.2 million in Berubicin costs as the clinical trial was closed out after enrollment and patient treatments were completed, alongside approximately USD 0.5 million lower TPI 287 Manufacturing costs, partly offset by USD 0.4 million of higher personnel expense.

On the administrative side, the USD 0.7 million increase came from consulting services of USD 0.5 million, primarily related to Business development, and headcount expenses of USD 0.4 million.

Nine-Month Results

For the nine months, research and development was USD 5,636 thousand versus USD 6,607 thousand and general and administrative was USD 4,705 thousand versus USD 3,393 thousand, bringing total operating expenses to USD 10,341 thousand versus USD 10,000 thousand. Interest income was USD 330 thousand versus USD 118 thousand.

Net loss was USD 10,024 thousand versus USD 9,895 thousand, or USD 1.65 per share versus USD 25.60, on 6.1 million weighted average shares versus 386,548.

The company reports no revenue, so the operating loss for the nine months equals total operating expenses of USD 10,341 thousand.

Strategy and Corporate Background

The company was organized as a Nevada corporation in July 2017. In the first quarter of 2026 it announced a new executive team and a new corporate strategy "focused on securing the rights to and developing innovative therapies", a change that shifts the research spending profile from earlier programs.

Interest expense was USD 3 thousand in the quarter and USD 13 thousand for the nine months, and total other income was USD 166 thousand versus USD 35 thousand.

The Balance Sheet shows cash and cash equivalents of USD 17,212 thousand at September 30, 2026 versus USD 7,201 thousand at December 31, 2025, and total current Assets of USD 18,050 thousand. Total liabilities were USD 2,359 thousand versus USD 4,100 thousand, and the notes payable balance of USD 328 thousand at year-end was gone. Net cash used in Operating Activities was USD 10,961 thousand versus USD 10,759 thousand, which the filing says mainly included clinical trial costs, officer compensation, insurance and consulting fees.

Items to Follow

Reference points include the pace of new in-licensing under the revised strategy, general and administrative spending after the Leadership change, the share count and the interest income earned on the cash balance.